MedLab Clinical
MedLab Clinical Limited (ASX:MDC) is a healthcare company with a focus on providing therapeutic pathways for chronic diseases. The company operates primarily out of Australia—with an organic chemistry set up in Southern California and additional offices in Malta and London—and has a market capitalisation of approximately $80 million.
MedLab is currently involved in the development of numerous medicinal products targeting everything from antibiotics to insulin, as well as therapies aimed at treating conditions such as obesity and depression. However, it has been attracting serious attention for its research into cannabis-based medicine targeted at pain management—particularly chronic oncology pain—which is an increasingly lucrative field.
The company takes a research-driven approach to the market and has a diversified product offering which already includes several cannabinoid products such as NanaBis and NanaBidial. MedLab have also developed a nano-particle medicine delivery system known as Nanocelle, which is being applied to its medicines, off-patent drugs and nutritional products.
YouTube Disclaimer
The Green Fund Pty Ltd (ACN 623 690 362) (“The Green Fund”) is a Corporate Authorised Representative (number 1277069) of Amplus Global Pty Ltd (ACN 162 631 325), the holder of Australian Financial Services Licence number 505929.
Any financial product advice provided in this video is general in nature. Any content in this video does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product.
The Green Fund believes the information contained in this video is correct. All information, opinions, conclusions and estimates that are provided are included with due care to their accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability. The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within this video.
It is important to note that all financial product or instrument transactions involve risks and past performance is not an indicator of future performance.
We note that the subject contained in this video may represent illegal activity in certain jurisdictions. Whilst we do not condone any acts which are contrary to any such laws, we understand that viewers in those jurisdictions which have decriminalised cannabis may find this video of interest.
MedLab is currently involved in the development of numerous medicinal products targeting everything from antibiotics to insulin, as well as therapies aimed at treating conditions such as obesity and depression. However, it has been attracting serious attention for its research into cannabis-based medicine targeted at pain management—particularly chronic oncology pain—which is an increasingly lucrative field.
The company takes a research-driven approach to the market and has a diversified product offering which already includes several cannabinoid products such as NanaBis and NanaBidial. MedLab have also developed a nano-particle medicine delivery system known as Nanocelle, which is being applied to its medicines, off-patent drugs and nutritional products.
YouTube Disclaimer
The Green Fund Pty Ltd (ACN 623 690 362) (“The Green Fund”) is a Corporate Authorised Representative (number 1277069) of Amplus Global Pty Ltd (ACN 162 631 325), the holder of Australian Financial Services Licence number 505929.
Any financial product advice provided in this video is general in nature. Any content in this video does not take into account the objectives, financial situation or needs of any person, or purport to be comprehensive or constitute investment advice and should not be relied upon as such. You should consult a professional adviser to help you form your own opinion of the information and on whether the information is suitable for your individual objectives and needs as an investor. Where necessary, you should obtain a Product Disclosure Statement relating to the product and consider it before making any decision about whether to acquire the product.
The Green Fund believes the information contained in this video is correct. All information, opinions, conclusions and estimates that are provided are included with due care to their accuracy; however, no representation or warranty is made as to their accuracy, completeness, or reliability. The Green Fund disclaims all liability and responsibility for any direct or indirect loss, or damage, which may be incurred by any recipient through any information, omission, error, or inaccuracy contained within this video.
It is important to note that all financial product or instrument transactions involve risks and past performance is not an indicator of future performance.
We note that the subject contained in this video may represent illegal activity in certain jurisdictions. Whilst we do not condone any acts which are contrary to any such laws, we understand that viewers in those jurisdictions which have decriminalised cannabis may find this video of interest.
People In This Video
No users are tagged in this video
